AI assistant
IDEXX LABORATORIES INC /DE — Director's Dealing 2018
Aug 7, 2018
30016_dirs_2018-08-07_f5c6e46d-9c83-458c-9c78-4f282a5239ea.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2018-08-06
Reporting Person: Studer Jacqueline (CVP, Gen. Counsel & Secretary)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-08-06 | Common Stock | M | 8598 | $79.54 | Acquired | 14447 | Direct |
| 2018-08-06 | Common Stock | S | 5588 | $242.0963 | Disposed | 8859 | Direct |
| 2018-08-06 | Common Stock | S | 3010 | $242.8694 | Disposed | 5849 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-08-06 | Non-Qualified Stock Option (right-to-buy) | $79.54 | M | 8598 | Disposed | 2025-02-13 | Common Stock (8598) | Direct |
Footnotes
F1: Includes 24 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2018.
F2: Represents the weighted average sales price of the shares sold ranging from a low of $241.55 to a high of $242.51 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: Represents the weighted average sales price of the shares sold ranging from a low of $242.69 to a high of $243.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4: Grant of option to buy 7,165 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F5: Not applicable.